CAS 184475-35-2
:Gefitinib
Description:
Gefitinib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of non-small cell lung cancer (NSCLC) that harbors specific mutations in the epidermal growth factor receptor (EGFR). Its chemical formula is C22H24ClFN4O3, and it features a complex structure that includes a quinazoline core. Gefitinib works by selectively inhibiting the tyrosine kinase activity of the EGFR, thereby blocking downstream signaling pathways that promote cell proliferation and survival. This mechanism of action makes it particularly effective in tumors with activating mutations in the EGFR gene. Gefitinib is administered orally and is characterized by its moderate solubility in water and its ability to penetrate biological membranes, which is crucial for its therapeutic efficacy. Common side effects associated with gefitinib include skin rash, diarrhea, and liver enzyme elevations. Its pharmacokinetics are influenced by factors such as food intake and liver function, necessitating careful monitoring during treatment. Overall, gefitinib represents a targeted therapy that has significantly improved outcomes for patients with specific types of lung cancer.
Formula:C22H24ClFN4O3
InChI:InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
InChI key:InChIKey=XGALLCVXEZPNRQ-UHFFFAOYSA-N
SMILES:N(C=1C2=C(C=C(OC)C(OCCCN3CCOCC3)=C2)N=CN1)C4=CC(Cl)=C(F)C=C4
Synonyms:- (3-Chloro-4-fluorophenyl)[7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl]amine
- 4-(3-Chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline
- 4-(3′-Chloro-4′-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
- 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-
- Akos 91371
- Gefitinib
- Gefitinib Base
- Gefitinib(TINIBS)
- Gefitinib, Iressa, ZD1839
- Gefonib
- Geftinib
- N-(3-Chloro-4-Fluoro-Phenyl)-7-Methoxy-6-(3-Morpholin-4-Ylpropoxy)Quinazolin-4-Amine
- N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
- N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine
- Zd 1839
- Zd1839
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 20 products.
Gefitinib
CAS:Formula:C22H24ClFN4O3Purity:>98.0%(T)(HPLC)Color and Shape:White to Light yellow powder to crystalMolecular weight:446.91GEFITINIB FOR SYSTEM SUITABILITY CRS
CAS:GEFITINIB FOR SYSTEM SUITABILITY CRSFormula:C22H24ClFN4O3Molecular weight:446.9024Gefitinib
CAS:Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoiFormula:C22H24ClFN4O3Color and Shape:White PowderMolecular weight:446.1521N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
CAS:Formula:C22H24ClFN4O3Purity:98%Color and Shape:SolidMolecular weight:446.9024Gefitinib
CAS:Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations.Formula:C22H24ClFN4O3Purity:99.92% - >99.99%Color and Shape:White SolidMolecular weight:446.90Gefitinib
CAS:Formula:C22H24ClFN4O3Purity:≥ 99.0%Color and Shape:White to off-white powderMolecular weight:446.90Gefitinib (Standard)
CAS:Gefitinib (Standard) is a reference standard for research and analysis in studies involving Gefitinib. Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.Formula:C22H24ClFN4O3Color and Shape:SolidMolecular weight:446.90Gefitinib
CAS:N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amineFormula:C22H24ClFN4O3Purity:98%Molecular weight:446.9Gefitinib
CAS:RIPK2 protein kinase inhibitor; EGFR inhibitorFormula:C22H24ClFN4O3Purity:Min. 98 Area-%Color and Shape:PowderMolecular weight:446.9 g/molGefitinib - Bio-X ™
CAS:Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) protein. This inhibition is on the EGFR tyrosine kinase domain, where Gefitinib bindings to the ATP-binding site. As a a tyrosine kinase inhibitor, Gefitinib blocks tumor growth and has led to its use in slowing the progression of non-small cell lung cancer. Gefitinib also inhibits invasion and metastasis through inhibition of macrophage receptor interacting protein kinase 2 (RIPK2), rather than EGFR.Formula:C22H24ClFN4O3Purity:Min. 98 Area-%Color and Shape:PowderMolecular weight:446.9 g/molN-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
CAS:Formula:C22H24ClFN4O3Purity:98%Color and Shape:Solid, Light yellow crystalline powderMolecular weight:446.91Gefitinib-d6
CAS:Controlled ProductApplications Gefitinib-d6 is the labeled version of Gefitinib (G304000), which is an antineoplastic.
References Anderson, N.G., et al.: Int. J. Cancer, 94, 774 (2001), Hirata, A., et al.: Cancer Res., 62, 2554 (2002), Kris, M.G., et al.: J. Am. Med. Assoc., 290, 2149 (2003), Tamura, K., et al.: Expert Opin. Pharmacother., 6, 985 (2005)Formula:C22D6H18ClFN4O3Color and Shape:NeatMolecular weight:452.939
![N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0039KY.jpg&w=3840&q=75)
